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Summan Inherent resistance of colon cancer cells to cis-diamminedichloroplatinum(II) (CDDP) is partly
attributed to reduced drug penetration through plasma membrane. Amphotericin B (AmB). a polyene
antifungal antibiotic, has been shown to increase CDDP penetration and cytotoxicity on several non-digestive
cancer cell lines. We demonstrated here that AmB dramatically increases the penetration of CDDP. and to a
lesser extent that of carboplatin (Carbo-P) and oxaloplatin (L-OHP). in the primary resistant HT 29 human
colon cancer cells when drug incubation is performed in serum-free medium. The cytotoxicity of CDDP but
not that of Carbo-P and L-OHP was increased bv AmB. However. AmB-induced potentiation of CDDP
penetration and toxicity was almost completely abolished when cell incubation was performed in presence of
human serum. We investigated whether the dilution of human serum by a high osmotic power gelatine
solution (Lomol) could restore the positive effect of AmB on CDDP accumulation in HT 29 cells. Incubation
of cells with CDDP and AmB in pure Lomol resulted in a 6-fold increase in platinum cellular content.
However. addition of serum (25%o) in Lomol solution reduced to only 2-fold the increase in platinum cellular
content provoked bv AmB. These disappointing results show that AmB is probably uninteresting as a
modulator of CDDP resistance in clinical practice. The use of haemodilution to restore the positive AmB
effect on platinum cellular accumulation cannot be warranted.
Cisplatin (CDDP) is an important anti-cancer drug for the
treatment of many solid tumours, but its efficiency is low in
human colon cancer (Durant, 1980). Natural or acquired
resistance of cancer cells to CDDP could result from several
mechanisms. including CDDP inactivation by glutathione or
metallothionein. increased DNA repair (Timmer-Bosscha et
al.. 1992) or reduced drug uptake (Richon et al., 1987;
Andrews et al.. 1988; Bungo et al.. 1990). The mechanism of
natural resistance of human colon cancer to CDDP and
related compounds has not been clearly determined. We have
previously observed a lower drug accumulation in several
CDDP-resistant human colon cancer cell lines when com-
pared with sensitive cancer cell lines originating from human
oesophageal tumours (unpublished results). The use of drugs
that influence membrane permeability and which enhance
transmembrane drug transport could be a useful method to
circumvent the natural resistance of human colon cancer cells
to cisplatin. In the present paper, we studied the effect of
amphotericin B (AmB), a polyene antifungal antibiotic
known to increase the permeability of the plasma membrane,
on the accumulation and cytotoxicity of CDDP, and two
derived compounds, in human colon cancer cells. Experi-
ments were performed either in serum-free medium or in
pure human serum in order to mimic a clinical situation.
Materials and methods
Chemicals
Cisplatin (cis-diamminedichloroplatinum, CDDP) was pur-
chased as a formulation for clinical use from Roger Bellon
laboratories (Neuilly, France). Carboplatin (Carbo-P) was
provided by Bristol-Myers Laboratories (Paris, France) and
oxaloplatin (L-OHP) by Debiopharm (Lausanne. Switzer-
land). Amphotericin B (AmB) was supplied as a commer-
cially available formulation for intravenous administration
(Fungizone, Squibb Laboratory, Paris. France). Each vial
contained 50 mg of amphotericin B. 38 mg of sodium
deoxycholate, 10 mg of disodium phosphate and 0.9 mg of
monosodium phosphate. Sodium deoxycholate allows the
formation of a colloidal dispersion of AmB with an enhanced
solubility. Deoxycholate is a bile salt with lipophilic pro-
perties but, used alone, it did not potentiate CDDP accumu-
lation and cytotoxicity (data not shown). Lomol is a high
osmotic power hydroxyethyl starch solution in balanced saline
serum provided by Du Pont Pharma (Paris. France).
Cells and drug cjtotoxicity assay
The HT 29 colon cancer cell line originated from a colic
adenocarcinoma in a non-treated patient and was obtained
from ATCC (Rockville. MD. USA). The culture medium was
a mixture of Ham FIO medium (Whittaker, Walkersville.
MD. USA) and 10% fetal bovine serum.
Cell survival after drug treatment was assayed by a
modified colony-forming assay (Pelletier et al.. 1990). Cells
were removed from culture flasks by a 10 min incubation
with a mixture of 2.5 mg of trypsin and 0.2 mg of EDTA in
Hanks' medium without calcium or magnesium then seeded
at low density (20 x 10' per well) in 96-well culture plates
and cultured for 2 days before treatment. Cells were exposed
to drugs for 3 h either in serum-free Ham F1O medium or in
pure human serum. This short exposure of HT 29 cells to
pure human serum, in the presence or absence of the
different drugs. did not produce any immediate or delayed
decrease in cell viability when assayed by a trypan blue
exclusion test. A short 3 h exposure to CDDP was chosen
because the drug is rapidly cleared from patient plasma in
the first 2 h after venous injection (Loehrer & Einhorn.
1984). After treatment, cells were washed twice with
phosphate-buffered saline and cultured again for 6 additional
days in drug-free culture medium with an intermediate
refeeding. At the end of the experiment. the number of
adherent cells was measured by a methylene blue assay. Cells
were washed with phosphate-buffered saline, fixed by pure
ethanol and stained with methylene blue (10% in borate
buffer). Excess dye was flushed out with tap water. Cell-fixed
dye was eluted by 0.1N hydrochloric acid. Absorbance in
each well was measured at 620 mm wavelength on a scanning
microplate spectrophotometer (Multiskan. Flow Labora-
tories, Irvine, UK). Results were expressed as percentage of
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cell survival of control untreated cells. Each point was the
mean of three determinations. IC50 values were graphically
determined.
Platinum cellular accwnulation
Cells (106 cells per well) were seeded in six-well culture plates
and cultured for 2 days. Cells were treated with drugs for 3 h
then washed twice with phosphate-buffered saline. Cells were
scraped from culture plates using a rubber policeman. The
cell pellet was digested for 1 h in 1 N sodium hydroxide and
sonicated. The residue was diluted in distilled water and
injected into a Hitachi 27000 flameless atomic absorption
spectrophotometer equipped with a graphite furnace and a
Zeeman background corrector (ISF, Fontenay aux Roses,
France). In order to determine the protein content, an ali-
quot was removed from the sample before addition of
sodium hydroxide and assay was performed by the bicin-
choninic acid method (Bradford, 1976).
Patients
Serum was collected from informed neutropenic patients
presenting candidaemia treated in a haematological care unit.
Blood was collected before and at the end of the first AmB
infusion. AmB (1 mg kg-') in the form of Fungizone was
dissolved in distiled water, diluted in 50 ml of a lipid solu-
tion (Intralipid) and perfused over 1 h.
Results
Deleterious influence ofserwn on the AmB-induced
potentiation ofCDDP
In order to determine if the AmB-CDDP combination could
be clinically useful, we performed the next HT 29 cell treat-
ment in human serum. Serum provoked a significant but
limited diminution of the cytotoxicity of CDDP used alone
(Figure 4). The IC54 was increased from 4iLg ml-' in the
presence of protein-free Ham medium to 7.5 Lg ml1' when
incubation was performed in pure serum. Figure 5 shows
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Fge 2 Survival of HT 29 cells after a 3 h incubation with
CDDP diluted in Ham Flo medium. CDDP was used alone (0)
or in association with 5 (0). 10 (A) or 20 (0)) jugml-' AmB.
Each point is the mean of four determinations. s.d. was inferior
to 5% of the values.
Potentiation ofCDDP accumulation and cytotoxicity by AmB
determined in serum-free medium
The effect of AmB on CDDP, L-OHP and Carbo-P cellular
accumulation was first studied in HT 29 cells in the presence
of serum-free Ham FIO medium (Figure 1). Cellular
platinum content was strongly increased when HT 29 cells
were incubated with CDDP in the presence AmB. AmB-
induced enhancement of platinum cellular accumulation was
less pronounced for Carbo-P and L-OHP.
Figure 2 shows that 5-20 gml-' AmB increased the
cytotoxic effect of CDDP on HT 29 cells. AmB up to
20 Lgml-' had no toxicity by itself. The IC5( of CDDP
changed from 4;Lgml-' when the drug was used alone to
0.6, 0.5 or 0.3iLgml-' when it was associated with 5, 10 or
20Lgml-' AmB respectively. L-OHP (IC5, 4p±gml-') was
slightly more cytotoxic than Carbo-P (ICm0 9 Lgml-'), but
the efficacy of both drugs was not modified by Amb (Figure
3).
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Figwe 1 Intracellular platinum content in HT 29 cells after a
3 h incubation of cells with AmB and with 1o zgml-' CDDP
(0), Carbo-P (0) or L-OHP (V) diluted in Ham FIO
medium. Each point is the mean of three determinations. s.d. was
inferior to 5% of the values.
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Fuge 3 Survival of HT 29 cells after a 3 h incubation with (a)
Carbo-P or (b) L-OHP given alone (0) or associated (-) with
5 igml-' AmB.
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that cell incubation with serum completely abolished the
AmB-induced potentiation of CDDP. In accordance with
this. we observed that serum abolished the AmB-induced
increase of the cellular platinum content that was evident in
serum-free medium (Figure 6).
Cellular platinum content was measured after a CDDP
incubation of HT 29 cells in serum obtained from AmB-
treated patients (Figure 7). Platinum content was increased
only 1.6-fold in the presence of a patient serum that con-
tained 7.36 pg ml-' Amb but was not modified in presence of
serum from any of three other patients in whom AmB con-
centration was 5.23. 4.89 and 4.29 pg ml-'.
Effect ofserum dilution on the AmB-inducedpotentiation of
CDDP
As the potentiation of the CDDP accumulation and cytotox-
icity by AmB was strongly hampered in presence of human
serum, we investigated if dilution of the serum by an osmotic
fluid could restore in vitro the positive AmB effect on the
platinum cellular accumulation (Figure 8). Serum was mixed
with Lomol. a high osmotic power gelatine solution in
balanced saline serum that is commonly used in anaesthe-
siology as a blood replacement solution. When diluted in
pure Lomol. AmB lOpgml-' provoked a 6-fold increase in
the platinum content of HT 29 cells. Addition of human
serum in Lomol solution resulted in a dramatic decrease in
the AmB potentiating effect with only a 2-, 1.9- and 1.6-fold
increase in the platinum cellular content when 25%. 50% or
75% serum. respectively, was added in Lomol.
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Figre 6 Intracellular platinum content in HT 29 cells after a
3 h incubation with 10pLg ml-' CDDP and AmB diluted in Ham
FIO medium (0) or in human serum (0). Each point is the
mean of three determinations. s.d. was inferior to 5% of the
values.
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Figure 7 Intracellular platinum accumulation after incubation of
HT 29 cells in serum from AmB-treated patients. Cells were
incubated for 3 h with 10fig ml-' CDDP diluted in patient serum
collected before (M) or at the end (0) of a 1 h intravenous
infusion of AmB diluted in 50 ml of Intralipid. AmB concentra-
tions were 7.36. 5.23. 4.89 and 4.29pLg ml-' in the serum of
patients 1, 2. 3 and 4 respectively. In a parallel experiment. cells
were incubated with CDDP in presence of serum-free Ham FIO
medium supplemented (0) or not (U) with 5fpgmP-' AmB.
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Figre 4 Survival of HT 29 cells after a 3 h incubation with
CDDP diluted in protein-free Ham medium (0) or in pure
human serum (*).
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Figre 5 Survival of HT 29 cells after a 3 h incubation with
CDDP diluted in pure human serum. CDDP was used alone (U)
or in association with 5 (*). 10 (A) or 20 (0) pLgml
AmB.
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Figure 8 Intracellular platinum content after incubation of HT
29 cells in presence of human serum (S) and Lomol (L) at various
percentages. Cells were incubated for a 3 h with 10 g ml-'
CDDP in the presence (0) or absence (U) of IO gml '
AmB.
Data reported in the present work show that AmB markedly
increased the accumulation and cytotoxicity of CDDP on
HT29 colon cancer cells when incubation was performed in
serum-free medium. Similar results were observed in another
human colon cancer cell line (CaCo2), in a rat colon cancer
cell line (DHD K12/PROb) and in the TEI and TE2 cancer
cell lines originating from two human oesophagus carcino-
mas (data not shown). In vitro enhancement of CDDP
accumulation and cytotoxicity by AmB has already been
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reported in several non-digestive cancer cell lines (Valeriote et
al.. 1984: Masuda et al.. 1991; Monrkage et al.. 1991. 1993).
AmB is a macrolide polyene antifungal antibiotic (MW 924)
that binds irreversibly to the sterol components in the cell
membrane. AmB insertion in the plasma membrane leads to
the formation of 4-10 A pores and provokes a leak of
electrolytes and metabolites and increases the cellular perme-
ability to various drugs (Binet & Boland, 1988: Brajtburg et
al.. 1990a). The greater cytotoxicity of AmB in fungal cells
compared with mammalian cells is attributed to its greater
affinity for ergosterol than for cholesterol (Kotler-Brajtburg
et al.. 1974: Cheron et al.. 1988). In concordance with
Morikage et al. (1993). we observed that AmB and CDDP
must be given simultaneously in order to obtain the maximal
potentiating effect (data not shown). Perturbation of the
plasma membrane structure induced by AmB appears as
transient. even if the antifungal agent persists for a long time
in the cell membrane (Collette et al.. 1989). As AmB induced
only a reduced penetration of Carbo-P and L-OHP compared
with CDDP. it can be speculated that all the platinum-
derived anti-cancer drugs do not share the same pathway to
cross the plasma membrane.
HT 29 human colon cancer cells are extremely resistant to
CDDP and its derivatives. About 10-20% of cells are able
to survive after a 3 h treatment with drugs at 50 g ml'.
This serum level is far above the clinically achievable concen-
trations. which do not exceed 2-4jg ml-' for a few minutes
after an intravenous infusion. As AmB given at non-toxic
concentration dramatically decreased this high level of resis-
tance by increasing the intracellular platinum content. we
believe that the natural resistance of colon cancer cells to
CDDP is more probably the result of a reduced transmemb-
rane penetration than of an enhanced intracellular
detoxification. The necessity of a large increase in platinum
cellular content to produce a clear enhancement of CDDP
cytotoxicity in cancer cells is probably related to the very low
fraction (about 1%) of the DNA-bound platinum. whereas
most of the drug is complexed to cytosolic and nuclear
proteins (Pinto & Lippard. 1985).
The range of AmB concentration which is required to
produce an in vitro potentiation of CDDP is above the AmB
level reached in patient serum after the administration of
conventional doses of AmB. Binschadler et al. (1969)
reported that AmB serum concentrations ranged only from
0.5 to 2.5 gml-' after a 4h infusion of 0.4-1.5 mg kg-'
AmB diluted in 5% dextrose. Higher serum concentrations of
AmB (up to 6iLg ml-') were measured when AmB was
administered as a liposomal formulation (Brajtburg et al..
1990b). In the present work. AmB was administered to the
patients after dilution in a lipid solution (Intralipid). This
method permitted. like the liposomal formulation. the use of
a higher daily dose (up to 2 mg kg-' day-'). a reduced
general and renal toxicity. a shorter duration of infusion over
1 h and a conserved clinical efficacy of AmB on fungal
infections (Caillot et al., 1993). Despite the high AmB con-
centration obtained after the infusion of AmB-Intralipid,
CDDP accumulation was not or only slightly increased when
HT 29 cells were incubated with CDDP in the presence of
the serum from AmB-treated patients. The maximum inc-
rease of CDDP accumulation (1.6-fold for a 7.36jug ml-'
AmB concentration) was not sufficient to increase
significantly the CDDP cytotoxicity.
A major observation in this work was that the potentiating
effect of AmB on the CDDP accumulation and cytotoxicity
of HT 29 cells was dramatically hampered when the cell
incubation was performed in pure human serum instead of
serum-free medium. AmB is known to highly bind serum
protein. mainly lipoproteins (Block et al.. 1974). At a concen-
tration of 1.6 gg ml-', the mean binding of AmB to serum
proteins is 95%. Inactivation of the membrane effect of AmB
in presence of serum proteins could explain the disappointing
results of several clinical trials. AmB has been associated
with lomustine, doxorubicin and cyclophosphamide and
other antineoplastic drugs without evident proof of clinical
efficacy (Chabot et al., 1989; Presant et al.. 1980. 1987).
Despite the well-known potentiation of CDDP by AmB in
vitro, no conclusive results have been published on the
efficacy and toxicity of the AmB-CDDP association in
patients with CDDP-refractory tumours.
As haemodilution is a commonly used technique in anaes-
thesiology or in emergency care (Boldt et al., 1990), we tested
if dilution of human serum in a non-protein osmotic solution
could restore the AmB-induced potentiation of CDDP.
Unfortunately. we observed that even a low percentage of
serum (25%) in the replacement solution strongly hampered
the positive effect of AmB on the CDDP penetration in vitro.
As a complete replacement of blood by Lomol is unrealisable
in patients. further investigations using the haemodilution
technique to circumvent CDDP resistance by AmB are not
warranted
Considering our negative data. we do not presently advo-
cate clinical trials with the AmB-CDDP combination in
CDDP-refractory carcinomas, such as colon tumours. More-
over. combination of AmB and CDDP could have severe
drawbacks in vivo owing to the overlapping renal toxicity of
both drugs. We propose to seek other drugs which share the
same permeabilising activity as AmB on plasma membrane
but which display a reduced binding to serum proteins.
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